Posted by Michael Wonder on 20 Feb 2025
PTC Therapeutics announces FDA acceptance and priority review for vatiquinone NDA for the treatment of children and adults with Friedreich's ataxia
19 February 2025 - PDUFA target action date of 19 August 2025.
PTC Therapeutics announced today that the US FDA has accepted for filing the new drug application for vatiquinone for the treatment of children and adults living with Friedreich's ataxia.
